Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Human ClpP Activators: Design, Mechanisms, and ZK53
2026-08-30
The 2025 Future Medicinal Chemistry review organizes recent small-molecule strategies for human mitochondrial ClpP, emphasizing activator design, structure–activity relationships, and pharmacological evaluation. Its analysis positions compounds such as imipridone derivatives and ZK53 as tools for perturbing mitochondrial proteostasis while identifying selectivity, pharmacokinetic, and safety challenges that remain before broader therapeutic translation.
-
Melatonin Blocks Atrazine-Induced Renal Necroptosis
2026-08-29
The reference study identifies RIPK3-dependent necroptosis as a central mechanism of atrazine-induced kidney injury and shows that melatonin limits this damage in cellular and animal models. Its combination of pathway perturbation, mitochondrial and inflammatory readouts, and computational binding analysis provides a mechanistic framework for studying chemical nephrotoxicity.
-
Rucaparib (AG-014699) DNA Repair Workflows
2026-08-28
Rucaparib (AG-014699) enables controlled studies of PARP1 inhibition, persistent DNA damage, and cancer-cell radiosensitization. This workflow connects established prostate cancer assays with an emerging HCC strategy centered on SmD2-dependent splicing and BRCA1/FANC repair outputs.
-
Gap19: Selective Cx43 Hemichannel Blocker
2026-08-28
Gap19 enables selective interrogation of Cx43 hemichannel signaling while preserving gap junction communication, making it useful for astrocyte ATP assays, macrophage inflammation studies, and ischemia models. This workflow-focused guide connects dose selection, pathway readouts, and troubleshooting to practical neuroglial and immune experiments.
-
EPI-001: Androgen Receptor N-Terminal Domain Inhibitor
2026-08-27
EPI-001 is an androgen receptor N-terminal domain inhibitor designed for studies of ligand-dependent and ligand-independent AR signaling, with particular value in CRPC and AR-positive TNBC models. This guide translates its mechanism into practical dose-response, transcriptional, migration, and troubleshooting workflows.
-
Spirocyclic POM Analogues Target MmpL3 in TB
2026-08-27
The 2024 Bioorganic Chemistry study develops spirocyclic phenyl oxazole methyl derivatives as a new MmpL3-directed strategy against Mycobacterium tuberculosis. Compound 5c combined submicromolar activity with activity against drug-resistant clinical isolates, acceptable preliminary ADME and pharmacokinetic properties, and low cytotoxicity in THP-1 cells.
-
Reactive Oxygen Species Assay Kit: From Signal to Mechanism
2026-08-26
The Reactive Oxygen Species Assay Kit provides a practical route to intracellular superoxide measurement with a dihydroethidium (DHE) probe. This guide connects DHE signal interpretation with TrxR/MAPK immunology, assay controls, and decisions in oxidative stress research.
-
Anti Reverse Cap Analog for Synthetic mRNA
2026-08-26
Anti Reverse Cap Analog enables orientation-specific 5′ capping for synthetic mRNA workflows that demand strong translation and reproducibility. This guide connects ARCA optimization with practical reprogramming, gene-expression, and mRNA therapeutics research workflows, including controls and troubleshooting steps.
-
Leucovorin Calcium in Tumor–Stroma Assays
2026-08-25
Leucovorin Calcium, also known as calcium folinate, can serve as more than a methotrexate rescue reagent. This article explains how paired organoid–assembloid assays use folate rescue to distinguish tumor-intrinsic sensitivity from stromal modulation.
-
MMV Pandemic Box Compounds Against Resistant Isolates
2026-08-25
This study screened compounds from the MMV Pandemic Response Box against multidrug-resistant bacterial and fungal clinical isolates using microbroth dilution and complementary bactericidal assays. Its most meaningful contribution is the identification of several compounds with activity against resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Candida species, while also showing why persister and MFC/MIC analyses are useful beyond a single MIC endpoint.
-
Pitavastatin (NK-104): In Vitro Workflow Guide
2026-08-24
Pitavastatin (NK-104, SKU B1124) is a high-purity HMG-CoA reductase inhibitor for controlled studies of cholesterol biosynthesis, including HepG2 cell assays and related cardiovascular or atherosclerosis research workflows. This guide covers preparation, assay controls, and interpretation boundaries; the supplied information does not establish clinical use, animal dosing, or a validated cardiovascular disease model protocol.
-
Thrombin B Chain Fragment: Assay Strategy
2026-08-24
Explore how the Coagulation Factor II B chain fragment supports sequence-defined thrombin research without being mistaken for intact catalytic enzyme. This guide connects reagent identity, protease assay design, and lessons from selective 3CLpro inhibitor screening.
-
Mouse Tissue Lysis Kit (K1038) Protocol
2026-08-23
The Mouse Tissue Lysis Kit (K1038) prepares lysates from mouse tail, toe, or ear tissue for direct PCR-based genotyping without a separate DNA extraction or purification step. It is intended for molecular biology research and assay development, not diagnostic, clinical, or medical testing.
-
Tirbanibulin and HPV Oncogenic Pathways in HeLa
2026-08-22
A 2024 study shows that tirbanibulin suppresses proliferation in HPV-18-containing HeLa cells while reducing protein expression across Src–MEK-related, cell-cycle, invasion, and survival pathways. The findings extend tirbanibulin biology beyond tubulin and Src activity by proposing a mechanistic connection to HPV E6/E7 regulation and apoptosis-associated signaling.
-
GM 6001 (Galardin): Mechanism-to-Assay Guide
2026-08-22
GM 6001, also called Galardin, is a potent broad-spectrum MMP inhibitor for dissecting extracellular matrix remodeling and protease-linked signaling. This guide connects its biochemical profile with orthogonal assay design, meniscal healing research, EGFR transactivation inhibition, and vascular migration studies.